window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 10, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Eli Lilly

  • Clinical Development,Neurosciences,Partnerships & Funding,Research & Development

    AC Immune amends Lilly collaboration on Tau small molecules for Alzheimer’s disease

    AC Immune has amended its collaboration agreement with Eli Lilly [...]

    April 7, 2026
  • Artificial Intelligence,Drug discovery,Partnerships & Funding

    Insilico Medicine signs $2.75bn AI drug discovery deal with Eli Lilly

    Insilico Medicine has signed a drug discovery collaboration with Eli [...]

    March 31, 2026
  • Chronic diseases,Clinical Development,Clinical studies,Drug Development,Drug discovery,Gastroenterology,Immunology,Pharmaceuticals and therapeutics

    Patients with Crohn’s disease maintain steroid-free remission for three years with Lilly’s Omvoh (mirikizumab)

    Long-term VIVID-2 data show more than 90% of patients with [...]

    February 19, 2026
  • Cell & Gene Therapy,Clinical Development,Genetic Diseases,Research & Development

    Scribe Therapeutics secures milestone $1.5BN collaboration with Eli Lilly for in vivo CRISPR program

    Scribe Therapeutics has achieved a second success milestone in its [...]

    February 18, 2026
  • Biotech,Drug Delivery & Formulation,Obesity,Pharmaceuticals and therapeutics,Research & Development,Supply Chain & Logistics,Technology and platforms

    Nanexa looks to get under the skin of GLP-1s and beyond

    Nanexa says its long-acting subcutaneous technology could reduce the dosing [...]

    November 4, 2025
  • Chronic diseases,Pharmaceuticals and therapeutics,Regulatory Affairs

    NICE backs Lilly’s mirikizumab for Crohn’s disease treatment

    The National Institute for Health and Care Excellence (NICE) has [...]

    September 10, 2025
  • Artificial Intelligence,Drug Development,Partnerships & Funding,Technology and platforms

    Lilly launches $1 billion TuneLab AI platform to boost biotech drug discovery

    Eli Lilly and Company has launched TuneLab, a new artificial [...]

    September 10, 2025
  • Global health,Market Access & Commercialization,Pharmaceuticals and therapeutics,Regulatory Affairs

    Pharmaceuticals and therapeutics: Lilly to raise drug prices in Europe as it cuts US patient costs

    Lilly has voiced strong support for the US administration’s goal [...]

    August 20, 2025
  • Biologics & Biosimilars,Clinical Development,Patient Centricity,Regulatory Affairs

    NICE recommends Mirikizumab for moderately to severely active Crohn’s Disease after biologic failure

    Mirikizumab is now recommended by NICE for routine NHS use [...]

    July 14, 2025
  • Clinical Trials,Drug Development,Patient Centricity,Regulatory Affairs

    NICE backs mirikizumab for treatment-resistant Crohn’s disease

    The National Institute for Health and Care Excellence (NICE) has [...]

    May 30, 2025
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Genmab appoints Margarida Duarte as general manager for Europe and emerging markets
    Categories: Healthcare leadership, Mergers & Acquisitions, Movers & Shakers, Pharmaceuticals and therapeutics
  • Opella appoints former Reckitt executive Gonzalo Balcazar to lead Europe and Latin America
    Categories: Healthcare leadership, Market Access & Commercialization, Movers & Shakers, Pharmaceuticals and therapeutics, Startups and innovations
  • Orano Med appoints Frederic Desdouits as CEO to advance targeted alpha therapy pipeline
    Categories: Biotech, Healthcare leadership, Movers & Shakers, Oncology, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top